Baloxavir marboxil (baloxavir) for the treatment of influenza. 인플루엔자 치료를 위한 발록사비르 마르복실(발록사비르)
a prodrug of the cap-dependent endonuclease inhibitor baloxavir acid (“cap” refers to a 7-methyl guanosine that is added to the 5′ end of the host messenger RNA strand), was approved as a single-dose treatment for uncomplicated influenza A and B in Japan and the United States in 2018 and was recently approved in the United States for the treatment of influenza in patients who were at risk for complications. Baloxavir treatment within 2 days after the onset of illness shortened the duration of illness by approximately 1 day as compared with placebo and showed superior antiviral efficacy to both placebo and oseltamivir. 소스; 7/23/2020 NEUJM